Voriconazole Tablets

Marketed by: Aurobindo Pharma Ltd
Compare to: Vfend (Prism)
Indication: Aurobindo Pharma Ltd has received final FDA approval for Voriconazole Tablets, the therapeutic equivalent of Prism’s Vfend, in 50- and 200-mg dosage strengths. The product is indicated to treat fungal infections in patients 12 years and older.
Dosage Form: Tablets: 50 and 200 mg
For More Information: aurobindousa.com


Felbamate Tablets
Marketed by:
Mylan
Compare to: Felbatol (Meda Pharmaceuticals)
Indication: Mylan recently launched Felbamate Tablets, a generic equivalent of Meda Pharm’s Felbatol tablets, in 400- and 600-mg dosage strengths. The product is indicated as monotherapy or adjunctive therapy for the treatment of partial seizures, with and without generalization. The product may also be used in adults with epilepsy and as adjunctive therapy for treating partial and generalized seizures associated with Lennox-Gastaut syndrome in children.
Dosage Form: Tablets: 400 and 600 mg
For More Information: mylan.com


Imatinib Mesylate
Marketed by:
Sun Pharmaceutical Industries
Compare to: Gleevec (Novartis)
Indication: Sun Pharma recently launched Imatinib Mesylate, the therapeutic equivalent of Novartis’ Gleevec, in 100- and 400-mg tablet strengths. The product is indicated to treat Philadelphia chromosome– positive chronic myeloid leukemia in adult and pediatric patients.
Dosage Form: Tablets: 100 and 400 mg
For More Information: SunPharma.com


Nadolol Tablets, USP
Marketed by:
Camber Pharmaceuticals, Inc
Compare to: Corgard (Pfizer)
Indication: Camber Pharmaceuticals recently launched Nadolol Tablets, USP, the generic equivalent of Pfizer’s Corgard tablets, in 20-, 40-, and 80-mg tablet strengths. The product is a beta blocker indicated to treat high blood pressure and chest pain.
Dosage Form: Tablets: 20, 40, and 80 mg
For More Information: camberpharma.com